CN119343602A - 用于诊断非酒精性脂肪性肝病（nafld）或非酒精性脂肪肝炎（nash）的标记物 - Google Patents

用于诊断非酒精性脂肪性肝病（nafld）或非酒精性脂肪肝炎（nash）的标记物 Download PDF

Info

Publication number
CN119343602A
CN119343602A CN202380045370.4A CN202380045370A CN119343602A CN 119343602 A CN119343602 A CN 119343602A CN 202380045370 A CN202380045370 A CN 202380045370A CN 119343602 A CN119343602 A CN 119343602A
Authority
CN
China
Prior art keywords
protein
type
alpha
beta
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380045370.4A
Other languages
English (en)
Chinese (zh)
Inventor
斋藤崇人
中村骏太
梅田将史
青柳和宏
西井弘行
绫部时芳
中村公则
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of CN119343602A publication Critical patent/CN119343602A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
CN202380045370.4A 2022-06-07 2023-06-07 用于诊断非酒精性脂肪性肝病（nafld）或非酒精性脂肪肝炎（nash）的标记物 Pending CN119343602A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022-092192 2022-06-07
JP2022092192 2022-06-07
PCT/JP2023/021092 WO2023238881A1 (ja) 2022-06-07 2023-06-07 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）または非アルコール性脂肪肝炎（ｎａｓｈ）を診断するためのマーカー

Publications (1)

Publication Number Publication Date
CN119343602A true CN119343602A (zh) 2025-01-21

Family

ID=89118332

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380045370.4A Pending CN119343602A (zh) 2022-06-07 2023-06-07 用于诊断非酒精性脂肪性肝病（nafld）或非酒精性脂肪肝炎（nash）的标记物

Country Status (4)

Country Link
EP (1) EP4553503A1 (https=)
JP (1) JPWO2023238881A1 (https=)
CN (1) CN119343602A (https=)
WO (1) WO2023238881A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3273247A1 (en) * 2010-06-10 2018-01-24 Metanomics Health GmbH Methods for the diagnosis of liver diseases
US20170370954A1 (en) * 2014-11-19 2017-12-28 Metabolon, Inc. Biomarkers for Fatty Liver Disease and Methods Using the Same
CN108130370B (zh) * 2018-01-05 2020-11-17 武汉惠康达科技有限公司 Psmb8及其抑制剂在制备治疗脂肪肝及其相关疾病药物中的应用
KR20220140727A (ko) * 2020-02-10 2022-10-18 소마로직 오퍼레이팅 컴퍼니, 인코포레이티드 비알코올성 지방간염 (nash) 바이오마커 및 이의 용도

Also Published As

Publication number Publication date
WO2023238881A1 (ja) 2023-12-14
EP4553503A1 (en) 2025-05-14
JPWO2023238881A1 (https=) 2023-12-14

Similar Documents

Publication Publication Date Title
CN107326066B (zh) 用于膀胱癌检测的尿标记物
JP6707181B2 (ja) 早産のリスクがある妊娠女性を同定するためのキットまたはパッケージ、および、当該キットまたはパッケージの使用
KR102562614B1 (ko) 비침습적 방법을 이용한 치주 질환 진단용 키트
KR101478826B1 (ko) 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트
JP2020513574A (ja) 疾患の診断用組成物
WO2017146529A1 (ko) 대장암 진단용 조성물과 진단 마커 검출 방법
US20170052200A1 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
EP2382327B1 (en) Biomarker
KR102122452B1 (ko) 암의 진단용 조성물
CN120290732B (zh) lncRNA生物标志物在食管鳞癌诊断中的应用
US20140248637A1 (en) Composition for diagnosis of lung cancer and diagnosis kit of lung cancer
CN119343602A (zh) 用于诊断非酒精性脂肪性肝病（nafld）或非酒精性脂肪肝炎（nash）的标记物
KR101895767B1 (ko) 동맥경화증 진단용 바이오 마커 조성물
CN116219017B (zh) 生物标志物在制备卵巢癌诊断和/或预后的产品中的应用
WO2006019037A1 (ja) 肝線維化ステージの判定方法
TWI507412B (zh) Gastric cancer biological markers and their use, as well as gastric cancer-related detection methods
KR102751933B1 (ko) 자간전증의 바이오마커 및 이의 용도
CN110241217A (zh) 早期诊断胰腺癌的分子标记
KR101878974B1 (ko) 신장암 진단용 조성물과 진단 마커 검출 방법
KR20230160425A (ko) 췌장암의 진단용 조성물
CN103210312A (zh) 通过软骨酸性蛋白1 检测脑梗塞的方法
CN113528641A (zh) 基因组合在诊断糖尿病肾病中的应用
KR101903230B1 (ko) KCa2.3 채널 단백질을 이용한 혈관내피세포 기능 부전 진단용 조성물 및 이의 용도
KR20200145279A (ko) 신장이식 후 t세포 매개성 거부반응의 진단 또는 예측을 위한 소변 엑소좀 바이오마커
WO2012024302A2 (en) Biomarkers of cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination